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Abstract Objective: Several societies have proposed frameworks to evaluate the benefit of
oncology drugs; one prominent tool is the European Society for Medical Oncology Magnitude
of Clinical Benefit Scale (ESMO-MCBS). Our objectives were to investigate the extent of Eu-
ropean Medicines Agency (EMA)-approved cancer drugs that meet the threshold for ‘mean-
ingful clinical benefit’ (MCB), defined by the framework, and determine the change in the
distribution of grades when an adapted version that addresses the scale’s limitations is applied.
Methods: We identified cancer drugs approved by the EMA (2011e2016). We previously pro-
posed adaptations to the ESMO-MCBS addressing its main limitations, including the use of
the lower limit of the 95% confidence interval in assessing the hazard ratio. To assess the
MCB, both the original and adapted ESMO-MCBS were applied to the respective approval
studies.
Results: In total, we identified 70 approval studies for 38 solid cancer drugs. 21% of therapies
met the MCB threshold by the original ESMO-MCBS criteria. In contrast, only 11% of ther-
apies met the threshold for MCB when the adapted ESMO-MCBS was applied. Thus 89% and
79% of therapies did not meet the MCB threshold in the adapted and original ESMO-MCBS,
respectively.
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Conclusions: In most of the cancer drugs, the MCB threshold is not met at the time of
approval when measured using both ESMO-MCBS scales. Since approval status does not
translate into a MCB, stakeholders and decision makers should focus on the benefit/risk ratio
of anticancer drugs to assure an appropriate allocation of resources in health care systems.
ª 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
With the introduction of new fast-track approval path-
ways for modern anticancer therapies, there are
increasing uncertainties and limited evidence regarding
the clinical benefit of these drugs at the time they are
approved [1,2]. Between 2006 and 2015, 26 drugs,
including 14 anticancer therapies, have received condi-
tional marketing authorisation in Europe, despite
ambiguous benefit-risk profiles [1]. Two additional
accelerated licensing strategies were recently piloted by
the European Medicines Agency (EMA)dan adaptive
pathway and PRIME (PRIority MEdicines)dthat allow
for faster access to medicines [3]. Such regulatory
changes have profound impacts on national medicine
and cancer budgets, as well as the ability of health
technology appraisal mechanisms to reach evidence-
based decisions.
In addition, cancer drug approvals based on surro-
gate outcomes have become more commonplace [4],
lowering clinical trial costs, participant numbers, and
follow-up times [5,6], but often still require post-
marketing assessments of overall survival (OS) and
quality of life (QoL) [1,4]. And, although these studies
are often delayed or fail to fulfil their obligations, the
approval status remains firm [2,5,6]. Thus, surrogate
outcomes lead to faster medicine access, but poor cor-
relations with clinical benefit [1,2,4,7].
In recent years, a variety of frameworks were published
to assess the value of cancer treatments. The European
Society for Medical Oncology Magnitude of Clinical
Benefit Scale (ESMO-MCBS) attempts to support the
optimal use of limited health care resources, while offer-
ing a standardised and transparent tool to evaluate the
benefit of novel cancer therapies [8]. Recently, the
ESMO-MCBS has been applied in several studies, and an
adapted version was proposed for the use in the area of
Health Technology Assessment (HTA) [9e11].
Therefore, our objectives were to (1) evaluate the
extent of recently EMA-approved cancer drugs that
satisfy the ESMO-MCBS criteria for a ‘meaningful
clinical benefit’ (MCB) and (2) contrast these defini-
tions of MCB with the adapted ESMO-MCBS,
addressing limitations that were previously identified
[10,12,13].
2. Methods
2.1. Identification of approval studies
We included all approval studies of cancer drugs indi-
cated for solid tumours that received marketing
authorisation by the EMA between 1st January 2011
and 31st December 2016. The identification of the study
cohort was based on a former study that extracted all
anticancer drugs approved between January 2009 and
April 2016 [14]. However, we updated this list and
incorporated all cancer drugs approved for solid tu-
mours since 15th April 2016 until the end of December
2016 by using the European Public Assessment Reports
(EPARs) published by the EMA (http://www.ema.
europa.eu/ema/). The EPARs were also used as a
source of information regarding the identification of
the respective approval studies. We excluded the
following studies that fail to meet the inclusion criteria
for use by ESMO-MCBS [8]: single-arm studies, can-
cer drugs for non-solid tumours, generics, studies with
non-statistically significant results and studies with end-
points not amenable for scoring by ESMO-MCBS
(Supplementary Fig. A.1).
2.2. Data extraction and scoring
One author (NG) extracted and compiled efficacy data
as well as information on QoL and toxicities from the
published approval studies and the respective EPARs.
Subsequently, two authors (SW and JDP) assessed the
extracted data independently and blindly. Any dis-
agreements were reviewed and examined by the blinded
authors (NG, SW and JDP).
Two different ESMO-MCBS scales were applied to
the results of all identified approval studies (nZ 70): the
original ESMO-MCBS published by Cherny et al.
[8] and an adapted framework of the ESMO-MCBS for
utilisation in HTA practice [10]. In the adapted frame-
work, modifications of the original ESMO-MCBS were
applied, as outlined in Table 1 and Table A.4. In both
scales, only statistically significant end-points were
graded. Based on the subsequent order, one of the
following study end-points was used to generate an
ESMO-MCBS grade:
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1. Statistically significant OS results.
2. Any applicable statistically significant primary end-point (if
1 does not apply).
3. Any applicable statistically significant secondary end-point
(if 1 and 2 do not apply).
Two authors (CW and NG) scored the approval
studies by either utilising the original ESMO-MCBS or
the adapted ESMO-MCBS. Scoring was also performed
by two blinded authors (SW and JDP). Disagreements
between scores were reviewed and examined by the
scorers (SW, NG and JDP). MCB is defined as scores of
4 or 5 for treatments with palliative intent (on a scale of
1e5) and scores of A or B for therapies with curative
intent (on a scale of C to A), as per the original ESMO-
MCBS [8].
2.3. Data analysis
Extracted data were compiled into a data form designed
in Microsoft Office Excel 2010. We computed the 95%
confidence intervals (CIs) of the proportion of therapies
meeting the thresholds by bootstrapping with 1,000,000
draws. The calculations of the CIs were conducted in R
environment [15].
3. Results
3.1. Characteristics of the approval studies
In total, we identified 70 approval studies (for 38 drugs)
that were eligible to apply the original as well as the
adapted ESMO-MCBS framework (Table 2 and Table
A.4). The most common disease settings were mela-
noma (21%), lung (21%) and gastrointestinal cancer
(17%). In 35 studies (50%), parameters regarding QoL
Table 1
Modifications of the original ESMO-MCBS that attempt to address shortfalls of the framework.
Adapted ESMO-MCBS Original ESMO-MCBS
Generation of grades
Point estimate of the HR used Lower limit of the 95% CI of the HR used
Grade adjustments
Downgrades due to a negative median OS despite graded end-point showing a
statistically significant, positive difference (Forms 2a, b and c)
Not implicated
Downgrades or upgrades due to positive or negative differences, respectively,
of at least 10% in any grade 3 AEs (Forms 2a and b)
Upgrades due to statistically significantly less grade 3e4
toxicities impacting on daily well-being (Forms 2a and b)
Downgrades due to one or more statistically significantly
increased incremental toxicities (Form 2b)
Downgrades or upgrades due to positive or negative differences, respectively,
of at least 10% in the discontinuation rates (Forms 2a and b)
Not implicated
Downgrades due to no difference in QoL or no QoL assessment performed
and only PFS showing an improvement (Form 2b)
Downgrades due to no difference in QoL and only PFS
showing an improvement (Form 2b)
Downgrades or upgrades due to statistically significant negative or positive
differences (respectively) in QoL (Forms 2a and b)
Upgrades due to statistically significant positive differences
in QoL (Forms 2a and b)
Abbreviations: AE, adverse event, CI, confidence interval, HR, hazard ratio, PFS, progression-free survival, QoL, quality of life.
Table 2
Characteristics of eligible comparative EMA approval studies for solid
tumours (n Z 70).
Characteristics n %a
Treatment intention
Palliative 70 100
Indication (ICD-10 category)
Gastrointestinal cancer (C15eC26) 12 17
Lung cancer (C30eC39) 15 21
Melanoma (C43eC44) 15 21
Sarcoma (C45eC49) 2 3
Breast cancer (C50eC50) 7 10
Cervical carcinoma (C51eC58) 1 1
Ovarian and peritoneal cancer
(C51eC58 and C45eC49)
5 7
Prostate cancer (C60eC63) 6 9
Renal cell carcinoma (C64eC68) 4 6
Thyroid carcinoma and neuroendocrine
tumour (C73eC75)
3 4
QoL parameter
Not available 35 50
Available 35 50
Phase of the study
II 5 7
III 65 93
Statistically significant study end-points
OS 34 49
PFS 60 86
Other 4 6
Scored end-points
OS 33 47
PFS 34 49
Other 3 4
Sample size
Mean 686
Median 658
Range 153e1873
Abbreviations: QoL, quality of life; OS, overall survival; PFS,
progression-free survival.
a Deviation of 100% cumulative percentage may be caused by
rounding.
N. Gro¨ssmann et al. / European Journal of Cancer 82 (2017) 66e7168
were available. All therapies were palliative in intent.
The median sample size was 658. Statistically significant
OS and progression-free survival (PFS) results were
accessible in 49% and 86% of the studies, respectively.
3.2. Comparison of the two ESMO-MCBS frameworks
Fifteen (21%) of the 70 investigated indications met the
threshold for MCB using the original ESMO-MCBS
and eight (11%) therapies met MCB threshold using the
adapted ESMO-MCBS (Fig. 1). This resulted in 79%
(95% CI 68.6e87.1, n Z 55) of therapies that did not
meet the threshold for MCB using the original ESMO-
MCBS, of which the majority reached grade 2
(n Z 16, 23%) and grade 3 (n Z 31, 44%), while eight
(12%) therapies were associated with grades 0 and 1.
Eighty nine percent (95% CI 80.0e95.7, n Z 62) of
therapies did not meet the adapted ESMO-MCBS
threshold for benefit, which are distributed into the
grades 0e3 as follows: 11% (n Z 8) grade 0, 23%
(n Z 16) grade 1, 31% (n Z 22) grade 2 and 23%
(n Z 16) grade 3 (Supplementary Table A.1).
With respect to the distribution of all grades, a shift
from higher scores to lower scores can be observed when
the adapted ESMO-MCBS framework is applied
(Fig. 1); grade 3, particularly, was most common in the
original ESMO-MCBS compared with grade 2 in the
adapted ESMO-MCBS. In addition, an increase of 22%
(n Z 16) in therapies with grades 0 and 1 was observed
in the adapted ESMO-MCBS compared with the orig-
inal framework. As shown in Tables A.2 and A.3, the
proportion of drugs meeting MCB thresholds varied
across cancers and between ESMO-MCBS frameworks.
4. Discussion
Approximately, 800 drugs and vaccines are currently
under investigation in clinical trials for the treatment of
cancer. Roughly, 80% of those are first-in-class thera-
pies, and around 73% are intended as personalised and,
therefore, targeted medicines [16]. Global costs for
anticancer therapies have increased in the last decade,
particularly due to targeted agents and immunother-
apies [16,17]. On these grounds, and due to the fact that
the number of cancer therapies in development is
continuing to rise [16], policy-makers and stakeholders
are facing potential challenges. In this study, we sought
to not only address the clinical benefit of recently EMA-
approved cancer drugs, but to also address the potential
limitations of the original ESMO-MCBS scale by
applying an updated ESMO-MCBS framework to the
same cohort of drugs (Table 1 and Table A.4). With
respect to the original ESMO-MCBS, 21% of the ther-
apies met the MCB threshold. In contrast, 10% fewer
therapies met the threshold for MCB when the adapted
ESMO-MCBS was applied, which is not surprising,
given the more strict criteria imparted by the adapted
framework (Table 1). In both cases, meaningful benefit
is lacking in the vast majority of EMA-approved cancer
medications over the last 5 years: 89% (95% CI
80.0e95.7) and 79% (95% CI 68.6e87.1) of therapies do
not meet the MCB threshold in the adapted and original
ESMO-MCBS, respectivelyda striking finding, given
that on a minority of novel cancer agents are deemed to
be clinically meaningful to patients.
The discrepancies between the adapted and original
ESMO-MCBS scores (Table 1 and Table A.4) shed light
Fig. 1. Comparison of the original and adapted ESMO-MCBS grades of all EMA-approved drugs for solid tumours (2011e2016).
N. Gro¨ssmann et al. / European Journal of Cancer 82 (2017) 66e71 69
on areas of potential improvement for the original
ESMO-MCBS. The use of the lower CI limit for
generating ESMO-MCBS grades not only introduces an
optimistic perspective, but also systematically favours
drugs with a low certainty in resultsda systematic bias
that should be avoided in an evidence-based value
framework. As in this study, a lowered realisation of the
arbitrary benefit threshold when the best estimate of the
HR is used has been previously in a different cohort of
anticancer agents [9]. The adapted ESMO-MCBS also
focuses on any toxicity data presented in the trial,
adjusting grades by a threshold percentage difference in
experimental and control toxicities in forms a and b
(Table 1 and Table A.4), as opposed to only statistically
significant toxicity end-points, which are less stringently
addressed in forms evaluating OS benefit. Given the
overt underscoring of harm that can occur in oncology
trials [18], especially in trials with positive primary end-
points [19], toxicity burden can be misrepresented at
baseline; therefore, any toxicity data presented should
be considered. Furthermore, the adapted ESMO-MCBS
takes into account the discontinuation rate of the drug
under assessment, which is a surrogate for drug intol-
erance either due to loss of efficacy or increased toxicity,
and should be a serious consideration when prescribing
oncology medications [20]. For QoL data, both frame-
works downgrade one level if a drug only leads to PFS
improvement without demonstrating a QoL improve-
ment. However, the adapted ESMO-MCBS also down-
grades one level if no QoL assessment was performed,
since a paucity of QoL data at the time of scoring should
not paradoxically result in a superior grade [13]. This is
a moot point in terms of MCB, as the maximum grade
obtained for PFS end-points with no QoL improvement
by the original ESMO-MCBS would fall below thresh-
olds (i.e. 3); this still may be important, however, when
comparing absolute grades between trials. Most
importantly, the adapted framework addresses detri-
mental QoL outcomes in conjunction with OS, resulting
in possible downgrading that does not occur in the
original ESMO-MCBS. Finally, for the adapted ESMO-
MCBS, a one-level downgrade is applied if the median
OS is negative when the graded end-point shows a sta-
tistically significant, positive difference. Only, in this
case, a downgrade of two scores is performed, since OS
is the ‘gold standard’ with respect to patient-relevant
outcomes and PFS studies often apply cross-over
designs that may lead to invalid conclusions about the
real benefit of anticancer drugs [21]. Therefore, a nega-
tive OS benefit should adjust ESMO-MCBS grades
accordingly.
The primary rationale for the proposed adapted
ESMO-MCBS was to not only provide a value frame-
work that improves applicability of trial results, but to
also provide increased focus on patient-relevant out-
comes; the ultimate goal was to generate a grade that
may be considered a more accurate reflection of MCB.
The higher weighting of the aforementioned factors
avoids the introduction of a systematic bias towards an
optimistic perspective that can result in incorrect con-
clusions and implications when formally assessing MCB.
To our knowledge, this is the first study that applies an
adapted version of the ESMO-MCBS to a cohort of
trials addressing some of the frameworks limitations and
comparing framework outputs to the original ESMO-
MCBS. Our findings of benefit, focused on EMA-
approved therapies and defined by both the original
and a less-permissive adapted ESMO-MCBS, are in line
with the recently published data. Vivot et al., have
shown that many modern Food and Drug Administra-
tion (FDA)-approved cancer drugs in the United States
(US) do not offer a high clinical benefit using both the
ESMO-MCBS and the American Society of Clinical
Oncology (ASCO) Value Framework [22]. Kim & Pra-
sad [4] have also focused primarily on 5 years of cancer
drugs approved by the FDA, showing that the majority
of approved therapies had unknown effects or did not
have any improvement in OS; in 67% of instances, ap-
provals were also shown to be the result of surrogate
outcomes. In addition, some of our authors have
demonstrated that only one-third of anticancer therapies
from randomised trials of the last 5 years (notably of
which only a minority were FDA-registration trials)
meet ESMO-MCBS thresholds for MCB [9].
The major limitation in presenting an adapted
ESMO-MCBS framework is its lack of validation, which
is a pertinent strength of the original ESMO-MCBS: it
has been externally validated against results with those
of health technology assessments carried out across
Europe, showing agreement [23]. The original incarna-
tion of the ESMO-MCBS has been heavily peer-
reviewed for reasonableness, while the adapted has
not. Our goal was, therefore, not to replace the original
ESMO-MCBS, but, rather, further the discussion on
objectifying clinical benefit, as well as provide ‘real
world’ examples of anticancer agents scored against a
stricter outlook on benefit (Table A.4). In addition, we
used several exclusion criteria (Fig. A.1) that may lead
to a bias and trend towards more positive results,
especially since studies with non-statistically significant
data and single-arm studies were not considered. We
also did not address protracted survival benefit that may
be imparted by therapies providing a durable response,
as is explicitly, and importantly, addressed in the ASCO
Value Framework [24]; this should be a consideration in
future iterations of the ESMO-MCBS. Finally, as in the
original ESMO-MCBS, the adapted framework does
not explicitly consider cost, which is an important factor
in decision making, especially since the prices for anti-
cancer treatments are rising [17]. Since comparable
frameworks simply ‘drop’ the cost of the therapy as the
final input into the framework analysis [24], in a similar
vein, costs can be considered by the ESMO-MCBS once
a grade is established.
N. Gro¨ssmann et al. / European Journal of Cancer 82 (2017) 66e7170
Our results, in combination with other recently pub-
lished analyses, demonstrate that the threshold for MCB
is not met by the majority of EMA-approved cancer
drugs, with limited evidence on the clinical benefit
available at the time of approval in approximately half
of the study cohort. Hence, an approval status of an
oncology drug may not confer a relevant health benefit
for patients. In addition, approvals on the basis of a
paucity of evidence are bound to increase due to new
fast-track approval pathways, which is already a focus
of criticism in the US [1e3]. Therefore, stakeholders and
decision makers need to continually assess the benefit-
risk ratio of new cancer drugs to ensure a balanced
and an equitable distribution of resources in our health
care systems. In doing so, ESMO-MCBS provides an
opportunity to predict the MCB of oncology drugs in a
standardised way. Future iterations of the ESMO-
MCBS will need to incorporate additional cost-
effectiveness analyses that will be necessary to not only
determine the MCB of novel drugs, but to support the
allocative decisions on our scarce health care resources.
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